title: [Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience].
abstract: OBJECTIVE
  Our aim was to assess the long-term data regarding efficacy and safety of infliximab (IFX) treatment for refractory Crohn's disease (CD) patients in our tertiary teaching hospital.
  
  
  METHODS
  We have retrospectively analyzed the medical records of 89 CD patients who underwent IFX treatment between March 2003 and February 2011 at Kyung Hee University Hospital (Seoul, Korea). The primary outcome measurements were the rates of initial clinical response (CR) at 10 weeks after the 1st IFX infusion and sustained CR at the end of the follow-up. Overall adverse events related to IFX treatment were also evaluated.
  
  
  RESULTS
  The mean (SD) follow-up period of eligible 80 patients was 33.7 (21.9) months. A total of 77 patients (96%) showed initial clinical response, but 8 patients showed loss of response to IFX during the follow-up. Finally, 59 patients (59/77, 76.6%) showed sustained CR at the end of the study. Logistic regression analyses showed that an initial CR at 10 weeks was the independent predictor associated with sustained CR (OR 22.286, 95% CI 2.742-132.717, p=0.001). Overall adverse events reported in 18 patients (18/80, 23.3%), including 3 serious infection (pulmonary tuberculosis and herpes zoster).
  
  
  CONCLUSIONS
  Treatment with IFX was efficacious and relatively safe for refractory CD patients in Korea. An initial CR at 10 weeks was significantly associated with sustained CR.
authors.affiliation: Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
authors.forename: Yeon-Ju
authors.initials: YJ
authors.lastname: Kim
authors.forename: Jung-Wook
authors.initials: JW
authors.lastname: Kim
authors.forename: Chang Kyun
authors.initials: CK
authors.lastname: Lee
authors.forename: Hyun Jin
authors.initials: HJ
authors.lastname: Park
authors.forename: Jae-Jun
authors.initials: JJ
authors.lastname: Shim
authors.forename: Jae Young
authors.initials: JY
authors.lastname: Jang
authors.forename: Suk Ho
authors.initials: SH
authors.lastname: Dong
authors.forename: Hyo Jong
authors.initials: HJ
authors.lastname: Kim
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Kim
authors.forename: Young Woon
authors.initials: YW
authors.lastname: Chang
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006562:Herpes Zoster / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D016015:Logistic Models; D008297:Male; D016017:Odds Ratio; D012189:Retrospective Studies; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000209:etiology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab